Related Experiment Video
Updated: Dec 5, 2025
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Immunodominant proteins P1 and P40/P90 from human pathogen Mycoplasma pneumoniae
David Vizarraga1, Akihiro Kawamoto2,3, U Matsumoto4
1Instituto de Biología Molecular de Barcelona (IBMB-CSIC), Parc Científic de Barcelona, Baldiri Reixac 10, 08028, Barcelona, Spain.
Abstract:
Mycoplasma pneumoniae is a bacterial human pathogen that causes primary atypical pneumonia. M. pneumoniae motility and infectivity are mediated by the immunodominant proteins P1 and P40/P90, which form a transmembrane adhesion complex. Here we report the structure of P1, determined by X-ray crystallography and cryo-electron microscopy, and the X-ray structure of P40/P90. Contrary to what had been suggested, the binding site for sialic acid was found in P40/P90 and not in P1. Genetic and clinical variability concentrates on the N-terminal domain surfaces of P1 and P40/P90. Polyclonal antibodies generated against the mostly conserved C-terminal domain of P1 inhibited adhesion of M. pneumoniae, and serology assays with sera from infected patients were positive when tested against this C-terminal domain. P40/P90 also showed strong reactivity against human infected sera. The architectural elements determined for P1 and P40/P90 open new possibilities in vaccine development against M. pneumoniae infections.
Insights
Mycoplasma pneumoniae adhesion proteins P1 and P40/P90 structures reveal sialic acid binding in P40/P90. Antibodies targeting conserved P1 domains inhibit bacterial adhesion, suggesting vaccine potential.
Area of Science:
- Microbiology
- Structural Biology
- Immunology
Background:
- Mycoplasma pneumoniae causes atypical pneumonia.
- Motility and infection depend on P1 and P40/P90 adhesion proteins.
- These proteins form a transmembrane adhesion complex.
Purpose of the Study:
- Determine the structures of P1 and P40/P90 proteins.
- Identify the sialic acid binding site.
- Evaluate the potential for vaccine development.
Main Methods:
- X-ray crystallography
- Cryo-electron microscopy
- Antibody generation and testing
- Serology assays
Main Results:
- The structures of P1 and P40/P90 were determined.
- Sialic acid binds to P40/P90, not P1.
- Conserved P1 C-terminal domains are targets for inhibitory antibodies.
- P1 and P40/P90 show reactivity with infected patient sera.
Conclusions:
- Structural insights into P1 and P40/P90 advance understanding of Mycoplasma pneumoniae pathogenesis.
- The P40/P90 sialic acid binding site is a novel target.
- Conserved regions of P1 are promising for vaccine strategies.
- These findings offer new avenues for Mycoplasma pneumoniae vaccine development.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
